2025. Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy. Farmeconomia. Health Economics and Therapeutic Pathways. 26, 1 (Mar. 2025). DOI:https://doi.org/10.7175/fe.v26i1.1574.